Ignite Creation Date:
2025-12-24 @ 2:16 PM
Ignite Modification Date:
2025-12-26 @ 2:19 AM
Study NCT ID:
NCT06247995
Status:
RECRUITING
Last Update Posted:
2025-11-06
First Post:
2024-01-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-08-14
Start Date Type:
ACTUAL
Primary Completion Date:
2031-09-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-09-09
Completion Date Type:
ESTIMATED
First Submit Date:
2024-01-17
First Submit QC Date:
None
Study First Post Date:
2024-02-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-05
Last Update Post Date:
2025-11-06
Last Update Post Date Type:
ESTIMATED